Edition:
United States

People: Agenus Inc (AGEN.PH)

AGEN.PH on Philadelphia Stock Exchange

4.74USD
11:25am EDT
Change (% chg)

$-0.04 (-0.73%)
Prev Close
$4.78
Open
$4.81
Day's High
$4.83
Day's Low
$4.72
Volume
3,411
Avg. Vol
15,873
52-wk High
$8.66
52-wk Low
$2.65

Stein, Robert 

Dr. Robert B. Stein, M.D., Ph.D., is a Chief Scientific Officer of Agenus Inc. Dr. Stein leads our Research, Preclinical Development and Translational Medicine functions and helps shape our clinical development strategy for the Prophage Series vaccines and HerpV. In addition, he is leading the integration of 4-Antibody into our business. Dr. Stein brings over 30 years of experience and accomplishments in the pharmaceutical and biotech industry to the Agenus leadership team. Over the course of his career Dr. Stein has played a pivotal role in bringing eight drugs to the market including Sustiva, Fablyn, Viviant, PanRetin, TargRetin, Promacta, & Eliquis. Prior to joining Agenus he held a number of senior management positions including Chief Scientific Officer & Senior Vice President of Research for Ligand Pharmaceuticals, Executive Vice President of Research & Preclinical Development for Dupont Merck, President and Chief Scientific Officer for Incyte Pharmaceuticals, President of Roche Palo Alto and CEO of KineMed. Dr. Stein spent the early part of his career at Merck, Sharp and Dohme Research Laboratories.

Basic Compensation

Total Annual Compensation, USD 623,827
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 948,680
Fiscal Year Total, USD 1,572,510

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Garo Armen

2,283,530

C. Evan Ballantyne

--

Robert Stein

1,572,510

Christine Klaskin

601,228

Karen Valentine

864,071

Ozer Baysal

593,602
As Of  30 Dec 2014